SLS

SELLAS Life Sciences Group, Inc.

Recommendation Details

PortfolioMidcap Short

DateOct 29, 2026

ForecastQ Daily Probabilities

53.6%

52.4%

63.8%

Company Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Recent News & Events

Imminent Phase 3 REGAL topline readout this quarter is the dominant binary catalyst; reaching the 80th event triggered a sharp selloff, creating high two-sided volatility risk into the data.

Clinical Trial Milestone

REGAL Phase 3 reaches 80th event, triggering final analysis

SELLAS announced the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in AML reached the pre-specified 80th death event, triggering database lock, unblinding, and final statistical analysis. Topline primary endpoint (overall survival) results are expected this quarter, making the stock a binary event-driven play with sharp near-term volatility. Shares fell ~15% on the news as no survival benefit was disclosed.

SELLAS Press Release (GlobeNewswire)

Analyst Commentary

Seeking Alpha flags excess survivors, unclear REGAL timing

A Seeking Alpha analysis published two days before the milestone noted REGAL shows significantly more survivors than planned but the cause is unknown and final data timing is unclear, rating SLS a Hold. This framing highlights the binary risk that a negative readout could cause a dramatic price drop given valuation already prices in high success probability.

Seeking Alpha

Clinical Data Readout (Upcoming)

SLS009 Phase 2 topline data expected in Q4 2026

SELLAS expects fourth-quarter topline data from its Phase 2 study of SLS009 (tambiciclib) in newly diagnosed AML, a secondary near-term catalyst that could add volatility alongside the REGAL readout. Positive data could broaden the pipeline narrative; timing overlaps the REGAL window.

Yahoo Finance

SLS

SLS

Company Information